Despite the promising efficacy and safety of antibodies targeting PD-1 and PD-L1 in treating tumors such as non-small cell lung cancer, melanoma, and ovarian cancer, current tumor immunotherapy approaches still face numerous challenges, including unresolved issues related to primary and acquired resistance [3]. Here, PDCD1 is linked to ovarian carcinoma.